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Abstract
Objectives: Diabetes is one of the most important 
endocrine diseases caused by complex reactions 
between genetic and environmental factors. Recent 
studies have shown that microRNAs play an impor-
tant role in the production, inhibition, and secretion 
of insulin. Identifying the relationship between key 
miRNAs that control the genes involved in the patho-
genesis of diabetes is clinically important because 
it provides a way to identify preventive methods or 
treatments. In the present study, the expression of 
miR135a in serum samples between women with 
Gestational diabetes mellitus (GDM), non-pregnant 
type 2 diabetes, and healthy pregnant women were 
compared with the control group.
Materials and methods: This study was a case-con-
trol study and non-random sampling method was 
used. The present study was conducted among 
four groups (healthy non-pregnant women (con-
trol), non-pregnant Diabetes type 2, GDM, and 
healthy pregnant). After serum separation, expres-
sion of miR-135a was measured using QRT-PCR 
technique and the results were analyzed by Stata 
and SPSS21 software.
Results: The results show that the mean expression 
of miR-135a gene in control group was 0.9 ± 0.06, 
control of pregnancy was 1 ± 0.1, GDM group was 
1.7 ± 0.3 and non-pregnant diabetic type 2 group 
was 6 ± 6 / 3. The results of analysis of variance 
showed that the mean difference of miR-135 gene 
expression was significant higher in the non- preg-
nant type 2 diabetes than GDM group (F = 2776.3, 
P <0.001).
Conclusion: The widespread role of miRNAs as 
post-transplantation gene regulators in gestational 
diabetes mellitus suggests that miR135a may act 
as a potential indicator of the prevention, treatment, 
and management of gestational diabetes  .
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